Welcome, Guest. Please login or register.
April 12, 2024, 05:23:03 pm

Login with username, password and session length

  • Total Members: 6307
  • Latest: golfer
  • Total Posts: 55125
  • Total Topics: 4851
  • Online Today: 61
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 30
Total: 30


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Modified Version of NASH Drug That Was Linked to Cancer Now Shows Promise  (Read 11016 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
A retooled version of the non-alcoholic steatohepatitis (NASH) drug FGF19 improved liver health on numerous fronts in a recent trial, MedPage Today reports. Previous research had indicated that FGF19 may promote hepatocellular carcinoma (HCC, the most common form of liver cancer). The new version is known as NGM282.

The Phase II study included 82 people with NASH, mild to advanced fibrosis of the liver and a minimum absolute liver fat content of 8 percent. The partcipants were randomly assigned to receive either 3 milligrams or 6 mg of NGM282 daily for 12 weeks or a placebo.

Findings were presented at the 52nd International Liver Congress in Amsterdam.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.